# RNA-seq Differential Expression Report

## Dataset & QC

- **Samples:** 7 total  
  - Control (untreated): 4 samples  
  - Experimental (treated): 3 samples  
- **Genes in raw matrix:** 14,599  
- **Library sizes:**  
  - Range: ~8.4M to ~21.9M reads  
  - Median library size: ~10.3M reads  
  - Some variability, but all within a typical RNA-seq range; DESeq2 can model this well.

**Low-count genes and filtering**

- Using a minimum total count threshold of **10** across all samples:
  - Low-count genes (removed): 4,678  
  - Genes retained for analysis: 9,921  
- This filtering reduces noise from extremely lowly expressed genes and improves power and multiple-testing correction without discarding the majority of expressed genes.

## Differential Expression

Analysis: DESeq2-style differential expression with **condition = treated vs untreated**, untreated as the reference, FDR (adjusted p-value) threshold **α = 0.05**.

- **Genes tested:** 9,921  
- **Significantly differentially expressed genes (padj < 0.05):** 836  

Top significant genes (by adjusted p-value):

- **FBgn0039155**  
  - baseMean: 730.6  
  - log2FC: **-4.62** (strongly down in treated vs untreated)  
  - padj ≈ 1.8 × 10⁻¹⁵⁹  

- **FBgn0025111**  
  - baseMean: 1501.4  
  - log2FC: **+2.90** (strongly up in treated)  
  - padj ≈ 8.5 × 10⁻¹¹⁰  

- **FBgn0029167**  
  - baseMean: 3706.0  
  - log2FC: **-2.20**  
  - padj ≈ 3.7 × 10⁻¹⁰⁶  

- **FBgn0003360**  
  - baseMean: 4342.8  
  - log2FC: **-3.18**  
  - padj ≈ 1.1 × 10⁻¹⁰³  

- **FBgn0035085**  
  - baseMean: 638.2  
  - log2FC: **-2.56**  
  - padj ≈ 1.8 × 10⁻⁷³  

Additional notable hits (still extremely significant):

- **FBgn0000071**: log2FC +2.68  
- **FBgn0051092**: log2FC +2.33  
- Several other genes with |log2FC| ~2–4 and padj ≪ 10⁻³⁰.

These results indicate a robust transcriptional response to the experimental condition, with both strong up- and down-regulation across many genes.

## Pathway Enrichment

Enrichment was run using **FlyEnrichr** (Drosophila), splitting significant genes into up- and down-regulated sets and testing each against:

- **GO Biological Process 2018**
- **KEGG 2019**

DE threshold for input genes: **padj < 0.05**

Summary of gene sets used:

- Significant genes: 836  
- Up-regulated genes: 200 (183 successfully mapped/queried)  
- Down-regulated genes: 200 (181 successfully mapped/queried)  

### Up-regulated gene set

#### GO Biological Process (GO_Biological_Process_2018)

- **Total enriched GO terms:** 656  
- **Significant at FDR < 0.05:** 44  

Top enriched GO terms (FDR < 0.05):

1. **Hexose biosynthetic process (GO:0019319)**  
   - Adjusted P-value: 0.0056  
   - Overlap: 3 genes  
   - Genes: **Pgi; fbp; Tpi**

2. **Gluconeogenesis (GO:0006094)**  
   - Adjusted P-value: 0.0056  
   - Overlap: 3 genes  
   - Genes: **Pgi; fbp; Tpi**

3. **Septate junction assembly (GO:0019991)**  
   - Adjusted P-value: 0.0056  
   - Overlap: 5 genes  
   - Genes: **nrv2; pasi2; bou; cold; Tsf2**

4. **Myotube differentiation (GO:0014902)**  
   - Adjusted P-value: 0.0065  
   - Overlap: 5 genes  
   - Genes: **Gapdh1; siz; Pglym78; sls; Tpi**

5. **Mitotic sister chromatid segregation (GO:0000070)**  
   - Adjusted P-value: 0.0065  
   - Overlap: 6 genes  
   - Genes: **borr; CycB; gammaTub37C; sls; Hmr; aub**

**Interpretation (up, GO-BP):**

- Strong enrichment for **hexose biosynthesis and gluconeogenesis** indicates enhanced **carbohydrate metabolism and energy production**, with classic glycolytic/gluconeogenic genes (Pgi, Tpi, fbp) up-regulated.
- Enrichment of **septate junction assembly** suggests changes in **cell–cell junctions and epithelial/neuronal barrier structure**.
- **Myotube differentiation** points to **muscle or myofibrillar remodeling**, with metabolic and structural genes (e.g., Gapdh1, Pglym78, sls) involved.
- **Mitotic sister chromatid segregation** indicates some degree of **cell-cycle / proliferative activity** in specific cells under treatment.

#### KEGG (KEGG_2019)

- **Total KEGG terms:** 41  
- **Significant at FDR < 0.05:** 6  

Top KEGG pathways:

1. **Glycolysis / Gluconeogenesis**  
   - Adjusted P-value: 0.0052  
   - Overlap: 5 genes  
   - Genes: **Pgi; Gapdh1; fbp; Pglym78; Tpi**

2. **Drug metabolism**  
   - Adjusted P-value: 0.0052  
   - Overlap: 6 genes  
   - Genes: **GstE7; GstE8; CG6330; GstT3; CG17224; GstE11**

3. **Metabolism of xenobiotics by cytochrome P450**  
   - Adjusted P-value: 0.0373  
   - Overlap: 4 genes  
   - Genes: **GstE7; GstE8; GstT3; GstE11**

4. **ECM-receptor interaction**  
   - Adjusted P-value: 0.0373  
   - Overlap: 2 genes  
   - Genes: **Col4a1; wb**

5. **Glutathione metabolism**  
   - Adjusted P-value: 0.0373  
   - Overlap: 4 genes  
   - Genes: **GstE7; GstE8; GstT3; GstE11**

**Interpretation (up, KEGG):**

- Enrichment of **Glycolysis / Gluconeogenesis** aligns tightly with GO results: the treatment drives an **upshift in central carbon metabolism**, likely boosting ATP production and metabolic flexibility.
- **Drug metabolism**, **xenobiotic metabolism by P450**, and **Glutathione metabolism** point to **induction of detoxification pathways**, especially glutathione S-transferases (GstE7, GstE8, GstT3, GstE11). This suggests the treatment is perceived as a **chemical stress or xenobiotic**, leading to activation of stress-response and detox networks.
- **ECM-receptor interaction** indicates changes in **extracellular matrix and cell–matrix adhesion**, via genes like Col4a1 and wb, suggesting structural or microenvironment remodeling.

### Down-regulated gene set

#### GO Biological Process (GO_Biological_Process_2018)

- **Total enriched GO terms:** 600  
- **Significant at FDR < 0.05:** 1  

Top GO terms:

1. **Positive regulation of cell proliferation (GO:0008284)**  
   - Adjusted P-value: 0.0026  
   - Overlap: 7 genes  
   - Genes: **RecQ4; CG4793; stg; CycE; Galphaf; mtd; boi**  
   - This is the **only** GO term with FDR < 0.05.

Other (non-significant by FDR, but suggestive) terms:

2. **Regulation of hemocyte proliferation (GO:0035206)**  
   - Adjusted P-value: 0.1012  
   - Overlap: 4 genes  
   - Genes: **Dif; CG4793; mfas; Galphaf**

3. **Embryonic hindgut morphogenesis (GO:0048619)**  
   - Adjusted P-value: 0.1012  
   - Overlap: 4 genes  
   - Genes: **SPARC; Dad; tnc; bowl**

4. **Positive regulation of cellular process (GO:0048522)**  
   - Adjusted P-value: 0.1100  
   - Overlap: 5 genes  
   - Genes: **Orct2; RecQ4; stg; CycE; boi**

5. **Regulation of Rho protein signal transduction (GO:0035023)**  
   - Adjusted P-value: 0.1100  
   - Overlap: 3 genes  
   - Genes: **RhoGAP1A; Ziz; Exn**

**Interpretation (down, GO-BP):**

- The key significant signal is the **down-regulation of genes involved in positive regulation of cell proliferation**, including **CycE (Cyclin E), stg (string), RecQ4**, and others that drive cell-cycle progression.
- This strongly suggests that the treatment **suppresses proliferative programs**, consistent with a shift towards more quiescent, differentiated, or stressed states.
- Additional (non-FDR-significant) terms hint at reduced **hemocyte proliferation** and modulation of **Rho signaling** and morphogenetic programs, but those should be interpreted cautiously due to FDR > 0.05.

#### KEGG (KEGG_2019)

- **Total KEGG terms:** 39  
- **Significant at FDR < 0.05:** 0  

Top KEGG terms (none pass FDR < 0.05):

1. **ECM-receptor interaction**  
   - Adjusted P-value: 0.0988  
   - Overlap: 2 genes  
   - Genes: **CG3168; Hml**

2. **Fatty acid degradation**  
   - Adjusted P-value: 0.0988  
   - Overlap: 3 genes  
   - Genes: **CG3902; bgm; CG17544**

3. **Amino sugar and nucleotide sugar metabolism**  
   - Adjusted P-value: 0.1105  
   - Overlap: 3 genes  
   - Genes: **Gale; mmy; CG15771**

4. **Nitrogen metabolism**  
   - Adjusted P-value: 0.1105  
   - Overlap: 2 genes  
   - Genes: **CG9674; CAHbeta**

5. **Lysosome**  
   - Adjusted P-value: 0.1750  
   - Overlap: 4 genes  
   - Genes: **CG6656; MFS10; Sap-r; CG30269**

**Interpretation (down, KEGG):**

- No KEGG pathway reaches FDR < 0.05, so there is no statistically robust KEGG-level down-regulation signal.
- Trends suggest possible reductions in **ECM interactions**, **fatty acid degradation**, and some **metabolic/lysosomal functions**, but these remain speculative and should not be over-interpreted without more evidence.

## Interpretation & Recommended Next Steps

### Overall biological picture

Based strictly on the results:

1. **Metabolic activation and stress/detox response in treated samples**
   - The treatment leads to strong up-regulation of **glycolysis/gluconeogenesis** (e.g., Pgi, Tpi, fbp, Gapdh1, Pglym78) and enrichment of the **Glycolysis / Gluconeogenesis** KEGG pathway (FDR ~ 0.005).  
   - There is robust induction of **drug/xenobiotic metabolism and glutathione metabolism**, with multiple **Gst** family members up-regulated and enrichment in **Drug metabolism**, **Metabolism of xenobiotics by cytochrome P450**, and **Glutathione metabolism** (all FDR < 0.05).  
   - Together, this suggests the treatment acts as a **metabolic and chemical stressor**, driving **energy metabolism** and **detoxification systems**.

2. **Suppression of proliferative programs**
   - The only significantly enriched GO term among down-regulated genes is **positive regulation of cell proliferation**, including key regulators like **CycE** and **stg**.  
   - This indicates the treatment **actively represses cell-cycle progression and proliferation**. In many contexts, such a pattern is consistent with **anti-proliferative, cytostatic, or differentiation-inducing treatments**.

3. **Structural and differentiation changes**
   - Up-regulated enrichment in **septate junction assembly**, **ECM-receptor interaction**, and **myotube differentiation** suggests **remodeling of cell–cell junctions, ECM, and possibly muscle or contractile architecture**.  
   - This combination (decreased proliferation, increased junction/ECM and differentiation-related terms) is consistent with a shift toward **more differentiated, structurally mature, and less proliferative states**.

4. **Magnitude and confidence**
   - The DE analysis identifies **836 significant genes** from 9,921 tested, with some genes showing **very large log2 fold-changes (~±2–4)** and extremely small adjusted p-values (down to ~10⁻¹⁵⁹).  
   - Pathway results include multiple **GO and KEGG terms with FDR < 0.01**, particularly among up-regulated processes, supporting a **high-confidence** conclusion that the treatment profoundly perturbs metabolic and proliferative networks.

### Recommended next steps

1. **Gene-level validation**
   - Select representative **up-regulated** genes from key pathways:
     - Metabolism: **Pgi, Tpi, fbp, Gapdh1, Pglym78** (Glycolysis/Gluconeogenesis)
     - Detox: **GstE7, GstE8, GstT3, GstE11**
   - Select representative **down-regulated** cell-cycle genes:
     - **CycE, stg, RecQ4**  
   - Validate by **qRT–PCR** or **western blot** (if antibodies available) to confirm expression changes.

2. **Functional assays**
   - **Proliferation assays** (e.g., EdU incorporation, cell counts, mitotic index) to test the predicted **reduction in cell proliferation** under treatment.
   - **Oxidative stress/detox assays**:
     - Measure **glutathione levels** or **GST activity**.
     - Assess **sensitivity to additional xenobiotics** to see whether detox pathways confer protection.
   - **Metabolic profiling**:
     - Measure **lactate production**, **ATP levels**, or **metabolic flux** (e.g., Seahorse assays) to confirm increased **glycolytic flux**.

3. **Contextualization with phenotype**
   - Link these molecular changes to observable phenotypes (e.g., growth inhibition, changes in tissue structure, behavior, or survival), especially if this is a **Drosophila tissue or whole-animal model**.
   - If the treatment is a drug candidate, evaluate whether the combination of **anti-proliferative effects** and **metabolic/detox changes** aligns with the intended mechanism of action.

4. **Deeper computational analyses (optional)**
   - Perform **clustering** or **PCA** of the expression data to visualize how treated and untreated samples separate, and to identify co-regulated gene modules (e.g., metabolic vs cell-cycle clusters).
   - Integrate with **additional datasets** (e.g., other treatments, mutants) to see whether the same pathways are recurrently affected.
   - Map the identified genes onto **Drosophila-specific networks** (e.g., FlyBase, FlyMine) to explore regulatory interactions and candidate upstream regulators.

Overall, this dataset shows a clear, coherent response to the experimental condition: **up-regulation of metabolic and detoxification pathways** and **down-regulation of proliferative programs**, accompanied by **structural and differentiation-related changes**. These features strongly support a model where the treatment pushes cells toward a less proliferative, metabolically active, and stress-responsive state.